Key facts
- Yafei Biomedical Technology’s last known valuation is $843.9M (Nov 2024).
- It has raised $106.3M; the latest was Later Stage VC ($41.8M) in Aug 2025.
- Notable investors include CMG SDIC Fund, China Growth Capital, Haiwang Capital, Chengdu Bio-Town Investment, Hongfu Investment — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Yafei Biomedical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Yafei Biomedical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yafei Biomedical Technology
Developer of a delivery system designed to cure tumours. The company focuses on developing innovative anticancer drugs and chemical coupling technology, which upgrades traditional drug innovation to tumour microenvironment delivery, enabling improved drug efficacy and an expanded medication safety window.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2012
- Ownership
- Privately Held (backing)
Yafei Biomedical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yafei Biomedical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yafei Biomedical Technology in its N-PORT filings yet. We sweep new filings monthly.